Drug Said to Protect the Body from Radiation Sickness

According to an article at Gizmag, researchers in the US and Israel have developed a drug that provides a sort of protection against radiation sickness.

Sounds a little too good to be true. But if it is true, the medication could not only help victims of nuclear fallout, but it could also allow for higher doses of radiation to be used in cancer therapies without fear of further sickening or even killing the patient.

In this respect, the drug could be a major breakthrough in cancer treatment.

Administered by injection, the preventative medication does its job by "suppressing the 'suicide mechanism' of cells hit by radiation, while at the same time enabling them to recover from the radiation-induced damage that triggered the suicide mechanism in the first place."

The medication is the brain-child of Professor Andrei Gudkov, Chief Scientific Officer at Cleveland BioLabs, and it could go up for FDA approval as soon as late 2010.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap